文献速递泌尿男性生殖肿瘤

循环脂质组合PCPro与转移性激素敏感性前列腺癌临床结局的关联:ENZAMET III期随机试验的事后分析(ANZUP 1304)

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).
PubMed 文献 · Ann Oncol · 2025-05-20

该研究为ENZAMET III期随机试验的事后分析,纳入866例转移性激素敏感性前列腺癌患者,采用液相色谱-质谱法检测血浆PCPro状态。基线PCPro阳性(13.4%)者总生存和临床无进展生存显著更短;PCPro状态为独立预后因素,且PCPro阳性者从恩扎卢胺对比非甾体抗雄激素治疗中未获得总生存获益。

要点

  • 基线PCPro阳性者总生存更短(HR 1.81,95%CI 1.40-2.33),临床无进展生存更短(HR 1.65,95%CI 1.32-2.07)。
  • 恩扎卢胺对比非甾体抗雄激素改善PCPro阴性者总生存(HR 0.61),PCPro阳性者无获益(HR 1.10,交互P=0.024)。
  • 进展时PCPro阳性者总生存短于阴性者,中位总生存24-28个月对比42-45个月,与基线状态无关。

核心结论

  • PCPro状态是预后生物标志物,并可预测转移性激素敏感性前列腺癌中恩扎卢胺对比非甾体抗雄激素缺乏总生存获益。
  • 这些发现为测试可改变循环脂质谱的治疗药物提供了依据。

研究设计与样本

  • ENZAMET III期随机试验的事后分析,比较恩扎卢胺与非甾体抗雄激素。
  • 采用液相色谱-质谱法检测866例参与者(占ENZAMET试验队列77%)治疗前(n=866)和首次进展时(n=282)的血浆PCPro状态。
  • 评估结局为总生存和临床无进展生存。

主要发现

  • 基线PCPro阳性者占13.4%,其总生存显著短于PCPro阴性者(HR 1.81,95%CI 1.40-2.33)。
  • 基线PCPro阳性者临床无进展生存显著短于PCPro阴性者(HR 1.65,95%CI 1.32-2.07;P<0.0001)。
  • PCPro与关键临床预后因素共同建模时为独立预后因素(P<0.001)。
  • 恩扎卢胺对比非甾体抗雄激素改善PCPro阴性者总生存(HR 0.61,P<0.0001),但未改善PCPro阳性者生存(HR 1.10,P=0.69;交互P=0.024)。
  • 进展时PCPro阳性者总生存短于阴性者,与基线状态无关(中位总生存24-28个月对比42-45个月)。

关键数值与推荐

  • 基线PCPro阳性率13.4%。
  • 基线PCPro阳性对比阴性:总生存HR 1.81(95%CI 1.40-2.33),临床无进展生存HR 1.65(95%CI 1.32-2.07),P<0.0001。
  • 恩扎卢胺对比非甾体抗雄激素:PCPro阴性者总生存HR 0.61(P<0.0001),PCPro阳性者总生存HR 1.10(P=0.69),交互P=0.024。
  • 进展时PCPro阳性对比阴性:中位总生存24-28个月对比42-45个月。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzalutamide significantly improves overall survival (OS) of patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, ∼10% of patients will die within 2 years. PCPro is a plasma lipid panel associated with decreased OS in metastatic castration-resistant prostate cancer. In this study, we assessed the association between PCPro and clinical outcomes in mHSPC by carrying out a post hoc analysis of ENZAMET, the landmark phase III trial comparing enzalutamide with nonsteroidal anti-androgen (NSAA). PATIENTS AND METHODS: PCPro status was determined by liquid chromatography-mass spectrometry analysis of plasma samples from 866 participants (77% of the ENZAMET trial cohort), before treatment (n = 866) and at first progression (n = 282). Outcomes examined were OS and clinical progression-free survival (clinPFS). RESULTS: Participants with a positive PCPro status at baseline (13.4%) had a significantly shorter OS and clinPFS compared with those with a negative PCPro status [OS hazard ratio (HR) 1.81, 95% CI 1.40-2.33, clinPFS HR 1.65, 95% CI 1.32-2.07, P < 0.0001]. PCPro is an independent prognostic factor when modelled with key clinical prognostic factors (P < 0.001). Enzalutamide (compared with NSAA) improved the OS of PCPro-negative participants (HR 0.61, P < 0.0001), but not the survival of PCPro-positive participants (HR 1.10, P = 0.69; interaction P = 0.024). Participants who were PCPro positive at progression have a shorter OS than those who were negative, irrespective of baseline status (median OS 24-28 months versus 42-45 months). CONCLUSIONS: PCPro status is a prognostic biomarker and predictive of the lack of OS benefit from enzalutamide compared with NSAA in mHSPC. These findings provide a rationale for testing therapeutic agents that can modify circulating lipid profiles in mHSPC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lin HM, Scheinberg T, Portman N, et al. Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304). Ann Oncol. 2025. PMID: 40403846. doi:10.1016/j.annonc.2025.05.529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。